ExonHit Launches First Product in Alzheimer
ExonHit Therapeutics announced that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and academic centers conducting clinical trials in Alzheimer’s disease.
“Alzheimer’s disease is a multi-factorial and a complex pathology. Currently, its diagnosis is mainly based on clinical criteria, i.e., relies on subjective measurements. Including subjects who are not properly characterized may easily increase the cost of a clinical study and potentially jeopardize its success,” commented Loïc Maurel, M.D., President of the Management Board of ExonHit Therapeutics. “The use of AclarusDx™ Alzheimer’s test could be a tremendous asset for the pharmaceutical industry as it has the potential to identify populations of patients who might benefit the most from therapeutic advances in AD.”
The launch of AclarusDx™ Alzheimer’s test as a RUO product is the first step in ExonHit’s commercial strategy in which trial sponsors will send patient blood samples for analysis in ExonHit’s GLP-compliant laboratories in the US. In parallel, the Company is preparing the launch of its product in the clinical in vitro diagnostics (IVD) market with partners. ExonHit is anticipating a CE marking in Q4 2010 for a European launch in Q1 of 2011. Regarding US marketing approval, discussions have been initiated with the FDA to define the exact regulatory path to meet IVD requirements.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Differentiating amino acids: Foundation for direct sequencing of individual proteins developed
Research under high pressure - Why 3,000 bars are needed to take a comprehensive look at a protein
Oxford Gene Technology and Abcodia form Partnership - Companies Combine Expertise to Advance Biomarkers for the Early Diagnosis of Pancreatic Cancer
Targeting a large family of parasites - Potential drug target is identified
Sigma-Aldrich strengthens position in RNAi and cell-based assays
Watching the production of new proteins in live cells
Focus Diagnostics - First U.S. Laboratory to License Newly Discovered Coronavirus CoV-NL63 From Primagen
Scientists X-ray chocolate
AI-based analysis system for the diagnosis of breast cancer - For the first time, morphological, molecular and histological data are integrated in a single analysis
New organ-on-chip pilot seeks to reduce animal testing in consumer health industry - Cooperation between Bayer, the start-ups esqLABS and Dynamic42, and Placenta Lab of Jena University Hospital
A vast viral world in wastewater - How metagenomic sequencing helps to understand the spread of viruses
